Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.

CONCLUSIONS: Combined-modality therapy including adjuvant external beam pelvic radiotherapy yields excellent outcomes for patients with all subtypes of node-positive endometrial cancer. The most pronounced DSS advantage from adjuvant chemoradiotherapy was evident in women with non-endometrioid endometrial cancer.
PMID: 31109659 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - May 16, 2019 Category: Cancer & Oncology Authors: Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH Tags: Gynecol Oncol Source Type: research